UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2019

Commission File Number: 001-38764

Aptorum Group Limited

17th Floor, Guangdong Investment Tower
148 Connaught Road Central
Hong Kong
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On June 1, 2019, the Company will participate in the International Symposium on Digital Health hosted by the Chinese University of Hong Kong and the Investment Workshop hosted by Quamnet in Hong Kong. We are attaching a copy of the PowerPoint presentations that the Company will use at the events mentioned and other events, as Exhibit 99.1 and Exhibit 99.2 to this Report and such PowerPoints are incorporated herein by reference.

Neither this report nor the presentations attached hereto as Exhibit 99.1 and 99.2 constitute an offer to sell, or the solicitation of an offer to buy our securities, nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

The information in this Form 6-K, including Exhibit 99.1 and 99.2 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

EXHIBIT INDEX

Exhibit No.	Description
99.1	PowerPoint Presentation dated May 31, 2019
99.2	PowerPoint Presentation dated May 31, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 31, 2019

Aptorum Group Limited

By: /s/ Sabrina Khan
Sabrina Khan
Chief Financial Officer

Exhibit 99.1


SMARTPHARMA
APTORUM
NASDAQ: APM
aptorumgroup.com
aenco
aencan.com
REVOLUTIONISE
PHARMACEUTICAL
PROCESSES
WITH SMART
SMART PHARMACEUTICAL IS A SUBSIDIARY OF
APTORUM GROUP (NASDAQ: APM)


APTORUM
Nasdaq
APM
NasdaqListed
On 18th December 2018, Aptorum Group Limited listed on the NASDAQ (ticker symbol: APM). IPO stock price is USD 15.80. Latest stock price is over USD 28.00 with current market capital of over USD 800 M.
2
For illustrative purposes only.

The Expanding Universe of Aptorum









Ever expanding universe of drug IP

© Copyright 2019 Aptorum Group Limited

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

ACT- Accelerating the Commercialisation of Therapeutics

Traditionally, drug discovery and development ("3D") is a time-consuming, costly and high-risk business

TIME

~12 YEARS[2,3]

COST

USD 2.6 BILLION[3]

FAILURE RATE

86.2%

nearly 86.2%[4] of drug candidates entering phase 1 trials fails to achieve drug approval

[1]https://www.aptuit.com/ebook-drug-discovery
[2]https://www.sciencedirect.com/science/article/pii/S245230291600035X
[3]https://www.the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285
[4]https://academic.oup.com/biostatistics/article/20/2/273/4817524

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

APTORUM

ACT- Accelerating the Commercialisation of Therapeutics



COMPUTATIONAL ALGORITHMS AND BIG DATA

Protein docking, genetic simulation, immunology, genomics, bioimaging, animal studies, proteomics

REPURPOSE

Potentially skip preclinical and Phase I by using existing data or just need an abbreviated version

ORPHAN DISEASES

Potentially skip large-scale clinical trials

OUT-LICENSING OPPORTUNITIES

Immediate

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

APTORUM

TRADITIONAL 3D & ACT 3D

	Traditional 3D - Problems	Act 3D - Solutions
Time (years)	10-17 years[1] Drug Discovery: 3-10 years[2] Preclinical Development: 1 year Phase I: Several months[3] Phase II to market: 5.4 years[4]	5-6.5 years Drug Discovery: 1-1.5 year Preclinical Development: may not needed Phase I: May not needed Phase II to market: 3.9 years[4]
Cost	US$2.6 billion[5]	US$ 33 million[6]
Probability	↓ Low hit rate from discovery to commercialisation	Expect 5 - 10 candidates to potentially enter clinical trials every year ↑ Higher probability of success 30% approval rate for repurposed drugs[7]

1 http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/
2 Estimated based on the overall development time of 10-17 years
3 https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm
4 Source: Drug Discov Today. 2012;17(13-14):660-4.
5 https://www.the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285
6 Source: Key cost drivers of pharmaceutical clinical trials in the United States (PDF), pg 5 (123), Oncology https://www.ncbi.nlm.nih.gov/pubmed/26908540
7 https://www.dcatvci.org/11-value-chain-insights/114-drug-repurposing-and-repositioning-making-new-out-of-old#

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

LIFE EXAMPLES: Neuroblastoma

TARGET **A**



14 drugs identified

TARGET **B**

20 drugs identified

TARGET **C**

12 drugs identified





Wet Lab Validation	2019
Phase 3 Trial Done	2021
Regulatory Approval	2024
Commercialisation	2025
Total	6 years*

* Timeline is for illustrative purposes only. Actual timing and results may vary.

This slide merely shows an example of indications which the Smart-ACT may provide drug repurposing solutions. It is not a representation that we are actually developing a drug for this diseases and/or under the development timeline mentioned.

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

APTORUM

ACT- Accelerating the Commercialisation of Therapeutics





For illustrative purposes only.

© Copyright 2019 Aptorum Group Limited

APTORUM

ACT- Accelerating the Commercialisation of Therapeutics

ACT THERAPEUTIC PORTFOLIO VALUATION VERSUS PROJECTED CLINICAL ASSETS:
Commercialisation + Out-Licensing Monetization Strategies

[1]Smart Pharma internal estimates based on model assumptions. Details available upon request.
[2]https://www.ncbi.nlm.nih.gov/pubmed/26368540

Potential of ACT	
Orphan Diseases	7000
Pipeline	• 5 – 10[1] candidates potentially enter clinical trials each year • Expect 1st clinical asset[1] in 2020 and cumulatively 4 clinical assets[1] by 2023
Potential Asset Pipeline Valuation	• Projected mid-range value at US$42 billion[1] by 2023
Clinical Development Costs (Wet-lab, Phase 2, Phase 3)	• US$ 33 million[2] per cancer drug • US$ 120 million accumulated development costs by 2023
Return on Invested Capital	• Per drug candidate: 4x to 5x[1] (over 4 years) • **Perpetual pipeline:** Systematic pipeline of clinical assets targeting orphan diseases and unmet medical needs!

Value projections are illustrative only. All estimates and forward-looking projections are based on modeled assumptions, which we believe to be reasonable, and evidence based where applicable. However, such assumptions are subject to change based on newly emerging data and/ or evidence, which could lead to changes in some or all projections presented in this presentation. We disclaim any responsibility to update these projections in the event of such changes at any time in the future.

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.
© Copyright 2019 Aptorum Group Limited
APTORUM

APM Stock Performance (as of 27/5/2019)



Stock chart extracted from https://www.nasdaq.com/symbol/apm/interactive-chart

For illustrative purposes only.

© Copyright 2019 Aptorum Group Limited

APTORUM

DISCLAIMER

Certain information included in this presentation and other statements or materials published by Aptorum Group Limited (the "Company") are not historical facts but are forward-looking statements.

These forward-looking statements refer in particular to the Company's management's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. Forward-looking statements speak only as of the date of this presentation and, subject to any legal requirement, the Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice. Such forward looking statements are for illustrative purposes only. Forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company. These risks and uncertainties include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post-marketing data), decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates.

A detailed description of risks and uncertainties related to the Company's activities is included under the "Risk factors" section of the Company's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. This presentation contains statistics, data and other information relating to markets, market sizes, market shares, market growth, market positions and other industry data pertaining to the Company's business and markets. Such information is based on the Company's analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports. The Company, its affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry forecasts. Such data and forecasts are included in this presentation for information purposes only.

This presentation does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in the United States or any other jurisdiction. This presentation includes only summary information and does not purport to be comprehensive. No reliance should be placed on the accuracy or completeness of the information or opinions contained in this presentation.

© Copyright 2019 Aptorum Group Limited

CONTACT US

SMART PHARMA

E info@smtph.com

W www.smtph.com

APTORUM GROUP

T +852 2117 6611

E info@aptorumgroup.com

A 17/F, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong

W www.aptorumgroup.com

STAY IN TOUCH

t.me/Smtpharma

twitter.com/smtpharma

reddit.com/r/SmartPharma

facebook.com/smtpharma

medium.com/smart-pharma

linkedin.com/company/smtpharma

youtube.com/channel/UCOCte0Gg6EniovERJTow_2Q

Exhibit 99.2


APTORUM
OUR MISSION IS TO FACILITATE LIFE SCIENCE INNOVATIONS TO SERVE UNMET MEDICAL NEEDS
Corporate Presentation
NASDAQ Global Market: APM


APTORUM
Nasdaq
APM
NasdaqListed
On 18th December 2018, Aptorum Group Limited listed on the NASDAQ (ticker symbol: APM). IPO stock price is USD 15.80. Latest stock price is over USD 28.00 with current market capital of over USD 800 M.
2
For illustrative purposes only.

The Expanding Universe of Aptorum







Acticule: Non-Antibiotic Platform

Claves: Pioneering Druggable Platform in microbiome

APTORUM

Smart-Act: Accelerating drug development via systematic drug repurposing for orphan diseases

Ever expanding universe of drug IP

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

THE MECHANISMS OF ALS-4

ANTI-GOLDEN PIGMENT AGENT



- Staphyloxanthin is the golden yellow pigment of *S. aureus*
- The pigment protects the bacteria against oxidative stress produced by our immune cells.
- ALS-4 is intended to suppress one of the key enzymes in the pigment production process
- *S. aureus* without pigments are more susceptible to host immune clearance

mBio [8(5): e01224, 2017]]

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited APTORUM

in vivo AND *in vitro* EFFICACY OF ALS-4

ALS-4 is intended to inhibit *S. aureus* pigment production with an IC_{50} = 20nM



ALS-4 is observed to reduce bacterial load in mice



Acute treatment

Compound concentration: 1 mM;

Inoculum: 5 X 10^6 per mouse

Treatment: twice for first 7 days,

First inject: 30 min after infection



Delayed treatment

Compound concentration: 1 mM;

Inoculum: 2 X 10^7 per mouse

Treatment: twice for 7 days,

First inject: 11 days after infection

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited APTORUM

Diseases Associated with Microbiota

Digestive diseases

- *C. difficile* infection
- Colorectal cancer
- Inflammatory bowel disease
- Irritable bowel syndrome

Systemic diseases

- Obesity
- Diabetes
- Fatty liver
- Cardiovascular diseases
- Renal failure
- Depression
- Parkinsonism
- Autistic spectrum disorder

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

Aptorum Group Limited © 2019 – Confidential and Proprietary

Our Strategy

1. Novel therapeutics to reduce amount of harmful gut microbiota chemicals that cause diseases
2. Act in gut with high affinity and specificity
3. Non-absorbable and free from systemic toxicity
4. Hundreds of metabolites for various clinical indications
5. Sustainable pipeline of unlimited therapeutic potentials

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

Aptorum Group Limited © 2019 – Confidential and Proprietary

Smart-Act: Accelerating the Commercialization of Therapeutics

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

APTORUM

ACT- Accelerating the Commercialisation of Therapeutics

Traditional 3D

ACT 3D



COMPUTATIONAL ALGORITHMS AND BIG DATA
Protein docking, genetic simulation, immunology, genomics, bioimaging, animal studies, proteomics

REPURPOSE
Potentially skip preclinical and Phase I by using existing data or just need an abbreviated version

ORPHAN DISEASES
Potentially skip large-scale clinical trials

OUT-LICENSING OPPORTUNITIES
Immediate

[1]https://www.aptuit.com/ebook-drug-discovery/

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.
© Copyright 2019 Aptorum Group Limited
APTORUM

TRADITIONAL 3D & ACT 3D

	Traditional 3D - Problems	Act 3D - Solutions
Time (years)	10-17 years[1] Drug Discovery: 3-10 years[2] Preclinical Development: 1 year Phase I: Several months[3] Phase II to market: 5.4 years[4]	5-6.5 years Drug Discovery: 1-1.5 year Preclinical Development: may not needed Phase I: May not needed Phase II to market: 3.9 years[4]
Cost	US$2.6 billion[5]	US$ 33 million[6]
Probability	↓ Low hit rate from discovery to commercialisation	Expect 5 - 10 candidates to potentially enter clinical trials every year ↑ Higher probability of success 30% approval rate for repurposed drugs[7]

1 http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/
2 Estimated based on the overall development time of 10-17 years
3 https://www.fda.gov/forpatients/approvals/drugs/ucm405622.htm
4 Source: Drug Discov Today. 2012;17(13-14):660-4.
5 https://www.the-scientist.com/features/repurposing-existing-drugs-for-new-indications-32285
6 Source: Key cost drivers of pharmaceutical clinical trials in the United States (PDF), pg 5 (121), Oncology https://www.ncbi.nlm.nih.gov/pubmed/29988540
7 https://www.dcatvci.org/11-value-chain-insights/114-drug-repurposing-and-repositioning-making-new-out-of-old#

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.
© Copyright 2019 Aptorum Group Limited
APTORUM

LIFE EXAMPLES: Neuroblastoma

TARGET A



14 drugs identified

TARGET B

20 drugs identified

TARGET C

12 drugs identified



Wet Lab Validation	2019
Phase 3 Trial Done	2021
Regulatory Approval	2024
Commercialisation	2025
Total	6 years*

* Timeline is for illustrative purposes only. Actual timing and results may vary.

This slide merely shows an example of indications which the Smart-ACT may provide drug repurposing solutions. It is not a representation that we are actually developing a drug for this diseases and/or under the development timeline mentioned.

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2019 Aptorum Group Limited

APTORUM

ACT- Accelerating the Commercialisation of Therapeutics





For illustrative purposes only.

© Copyright 2019 Aptorum Group Limited

APTORUM

ACT- Accelerating the Commercialisation of Therapeutics

ACT THERAPEUTIC PORTFOLIO VALUATION VERSUS PROJECTED CLINICAL ASSETS:
Commercialisation + Out-Licensing Monetization Strategies

[1]Smart Pharma internal estimates based on model assumptions. Details available upon request.
[2]https://www.ncbi.nlm.nih.gov/pubmed/26908560

Potential of ACT	
Orphan Diseases	7000
Pipeline	• 5 – 10[1] candidates potentially enter clinical trials each year • Expect 1st clinical asset[1] in 2020 and cumulatively 4 clinical assets[1] by 2023
Potential Asset Pipeline Valuation	• Projected mid-range value at US$42 billion[1] by 2023
Clinical Development Costs (Wet-lab, Phase 2, Phase 3)	• US$ 33 million[2] per cancer drug • US$ 120 million accumulated development costs by 2023
Return on Invested Capital	• Per drug candidate: 4x to 5x[1] (over 4 years) • **Perpetual pipeline:** Systematic pipeline of clinical assets targeting orphan diseases and unmet medical needs!

Value projections are illustrative only. All estimates and forward-looking projections are based on modeled assumptions, which we believe to be reasonable, and evidence based where applicable. However, such assumptions are subject to change based on newly emerging data and/or evidence, which could lead to changes in some or all projections presented in this presentation. We disclaim any responsibility to update these projections in the event of such changes at any time in the future.

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.
© Copyright 2019 Aptorum Group Limited
APTORUM

APM Stock Performance (as of 27/5/2019)



Stock chart extracted from https://www.nasdaq.com/symbol/asm/interactive-chart

For illustrative purposes only.

© Copyright 2019 Aptorum Group Limited

APTORUM

DISCLAIMER

Certain information included in this presentation and other statements or materials published by Aptorum Group Limited (the "Company") are not historical facts but are forward-looking statements.

These forward-looking statements refer in particular to the Company's management's business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which are naturally subject to risks and contingencies that may lead to actual results materially differing from those explicitly or implicitly included in these statements. Forward-looking statements speak only as of the date of this presentation and, subject to any legal requirement, the Company does not undertake to update or revise the forward-looking statements that may be presented in this document to reflect new information, future events or for any other reason and any opinion expressed in this presentation is subject to change without notice. Such forward looking statements are for illustrative purposes only. Forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company. These risks and uncertainties include among other things, the uncertainties inherent in research and development of new products, including future clinical trial results and analysis of clinical data (including post-marketing data), decisions by regulatory authorities, such as the Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates.

A detailed description of risks and uncertainties related to the Company's activities is included under the "Risk factors" section of the Company's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. This presentation contains statistics, data and other information relating to markets, market sizes, market shares, market growth, market positions and other industry data pertaining to the Company's business and markets. Such information is based on the Company's analysis of multiple internal and third party sources, including information extracted from market research, governmental and other publicly available information, independent industry publications and information and reports. The Company, its affiliates, shareholders, directors, officers, advisors, employees and representatives have not independently verified the accuracy of any such market data and industry forecasts. Such data and forecasts are included in this presentation for information purposes only.

This presentation does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in the United States or any other jurisdiction. This presentation includes only summary information and does not purport to be comprehensive. No reliance should be placed on the accuracy or completeness of the information or opinions contained in this presentation.

© Copyright 2019 Aptorum Group Limited

APTORUM GROUP LIMITED
investor.relations@aptorumgroup.com
T +852 2117 6611
F +852 2850 7286